DOI resolved by resea
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial on resea.org. DOI 10.1016/s0140-6…
Anthony B. El-Khoueiry, Bruno Sangro, Thomas Yau, Todd S. Crocenzi, Masatoshi Kudo, Chiun Hsu, Tae‐You Kim, Su-Pin Choo
https://resea.org/10.1016/s0140-6736(17)31046-2